Roche Holding AG’s Japanese affiliate Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval in short order from Japan’s Ministry of Health, Labour and Welfare for the monoclonal antibody combination casirivimab/imdevimab, as Ronapreve, for SARS-CoV-2 infection.
The submission was made only on 29 June